COMMUNIQUÉS West-GlobeNewswire

-
Westleaf: A Truly Vertically-Integrated Cannabis Play -- CFN Media
19/02/2019 -
National Brain Tumor Society and the Brain Science Foundation Partner to Fund Research for Most Common Brain Tumor Type
19/02/2019 -
Canadian Startup Enhanced Medical Nutrition (“EMN”) Completes Oversubscribed Seed Round Funding
19/02/2019 -
U. S. FDA Grants Clearance for Ion by Intuitive
19/02/2019 -
BioCorRx Announces Formation of Scientific Advisory Board
19/02/2019 -
Diamond CBD Books Over $200,000 in Orders in 3 Days at Tobacco Plus Expo in Las Vegas
19/02/2019 -
TOMI Environmental Solutions, Inc. Announces Relocation of Its U.S. Corporate Headquarters
19/02/2019 -
Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management
19/02/2019 -
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 janvier 2019
19/02/2019 -
MediPharm Labs Announces Listing on Frankfurt Stock Exchange
19/02/2019 -
Generex Biotechnology Subsidiary Regentys Corporation Receives Approval of Japanese Patent for Extracellular Matrix Hydrogel (Regentys ECMH™)
19/02/2019 -
Radius Health to Present at Leerink Partners 8th Annual Global Healthcare Conference
19/02/2019 -
Innovation Pharmaceuticals Receives New Patent for Compounds for Use in Treatment of Oral Mucositis
19/02/2019 -
RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia
19/02/2019 -
Precision Therapeutics Inc. is Excited to Announce a Special Meeting of Stockholders and Commencement of Registered Exchange Offer
19/02/2019 -
Canada House Wellness Group Announces Unit Financing for $2 to $3 Million
19/02/2019 -
Letter to Shareholders from Curt Fairbrother, CEO The Medtainer™
19/02/2019 -
VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia
19/02/2019 -
Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin
19/02/2019
Pages